Related Experiment Video
Updated: Apr 18, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.8K
Defining the research category in pediatric Phase I oncology trials
1a Human Subjects Protection Program , Children's Hospital Los Angeles , Los Angeles , California , USA.
Accountability in Research
|January 31, 2015
Summary
Classifying pediatric oncology trials by risk is complex. These high-risk studies, often without direct benefit, pose challenges for Institutional Review Boards (IRBs) and informed consent.
Area of Science:
- Pediatric oncology research ethics
- Clinical trial risk stratification
- Institutional Review Board (IRB) challenges
Background:
- Clinical research in children is categorized by risk: minimal, more than minimal with benefit, or minor increase over minimal without benefit.
- Pediatric Phase I oncology trials involve severely ill children with cancer, aiming to determine safety, maximum tolerated dose (MTD), and dose-limiting toxicity (DLT).
- These trials can involve significant risks and often lack direct clinical benefit due to their design.
Purpose of the Study:
- To discuss the challenges in classifying pediatric oncology trials.
- To highlight the implications of risk classification on the informed consent process.
- To examine the specific problems faced by Institutional Review Boards (IRBs) in categorizing high-risk pediatric studies.
Main Methods:
- Review of existing risk classification frameworks for pediatric clinical research.
- Analysis of the unique characteristics of Pediatric Phase I oncology trials.
- Discussion of the ethical considerations and practical challenges for IRBs.
Main Results:
- Pediatric Phase I oncology trials present a unique challenge for risk classification due to high vulnerability and potential for significant risk without direct benefit.
- The classification impacts the informed consent process, requiring careful consideration by IRBs.
- Standard risk categories may not adequately address the complexities of these specific trials.
Conclusions:
- Accurate risk classification of pediatric oncology trials is crucial for ethical research conduct.
- IRBs require specific guidance to navigate the complexities of these studies.
- Further discussion is needed to refine classification systems for high-risk pediatric trials.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
367
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
367
01:11Clinical Trials: Overview
5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
01:16Clinical Trials
11.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
11.2K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
391
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
391
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
882
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
882
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
508
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
508